Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8599265 | 0.93 | ALDH1A1 (0.41) | ALDH1A1MEN1LMNAMAPTHPGD | |
| SCHEMBL28346231 | 0.93 | ALDH1A1 (0.41) | ALDH1A1MEN1LMNAMAPTHPGD | |
| SCHEMBL28799139 | 0.93 | ALDH1A1 (0.41) | ALDH1A1MEN1LMNAMAPTHPGD | |
| SCHEMBL28459651 | 0.83 | ALDH1A1 (0.38) | ALDH1A1MEN1LMNAMAPTHPGD | |
| SCHEMBL6593076 | 0.69 | ALDH1A1 (0.35) | ALDH1A1NOS3NOS1NOS2 | |
| SCHEMBL4064825 | 0.69 | ALDH1A1 (0.35) | ALDH1A1MEN1LMNAMAPTHPGD | |
| SCHEMBL13576631 | 0.69 | ALDH1A1 (0.35) | ALDH1A1NOS3NOS1NOS2 | |
| SCHEMBL10476883 | 0.69 | ALDH1A1 (0.35) | ALDH1A1MEN1LMNAMAPTHPGD | |
| SCHEMBL18419296 | 0.69 | — | — | |
| SCHEMBL10683142 | 0.67 | UGT2B17 (0.31) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021121-A1 | CANNABIS COMPOSITIONS AND METHODS | AIP ASSET MANAGEMENT INC. (CA) | 2026-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021121-A1 | CANNABIS COMPOSITIONS AND METHODS | CNR2, CNR1, CCT3 | ALDH1A1 4096/4885MEN1 3733/4885LMNA 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.